Berry Genomics Co.,Ltd (SHE:000710)
China
· Delayed Price · Currency is CNY 9.92
+0.17 (1.74%)
Apr 29, 2026, 3:04 PM CST
Berry Genomics Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 929.82 | 1,059 | 1,129 | 1,343 | 1,370 | Upgrade
|
| Other Revenue | - | 19.47 | 21.92 | 24.64 | 52.43 | Upgrade
|
| Revenue | 929.82 | 1,078 | 1,151 | 1,368 | 1,422 | Upgrade
|
| Revenue Growth (YoY) | -13.76% | -6.36% | -15.83% | -3.81% | -7.67% | Upgrade
|
| Cost of Revenue | 528.6 | 603.72 | 668.26 | 821.85 | 827.75 | Upgrade
|
| Gross Profit | 401.22 | 474.44 | 483.16 | 546.15 | 594.43 | Upgrade
|
| Selling, General & Admin | 364.23 | 357.18 | 404.55 | 463.21 | 456.17 | Upgrade
|
| Research & Development | 104.36 | 95.42 | 110.01 | 106.74 | 128.23 | Upgrade
|
| Other Operating Expenses | 3.81 | 10.64 | 4.67 | 3.76 | 2.84 | Upgrade
|
| Operating Expenses | 472.4 | 593.91 | 682 | 671.71 | 640.85 | Upgrade
|
| Operating Income | -71.18 | -119.47 | -198.84 | -125.56 | -46.41 | Upgrade
|
| Interest Expense | - | -9.83 | -16.35 | -17.64 | -20.3 | Upgrade
|
| Interest & Investment Income | - | 3.52 | 2.64 | 2.36 | 5.05 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.77 | -0.55 | -1.62 | 0.38 | Upgrade
|
| Other Non Operating Income (Expenses) | -117.67 | -2.59 | -0.37 | 2.79 | -5.26 | Upgrade
|
| EBT Excluding Unusual Items | -188.85 | -129.14 | -213.47 | -139.66 | -66.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | -6.38 | -40.18 | -82.67 | -144.31 | -49.13 | Upgrade
|
| Gain (Loss) on Sale of Assets | 5 | 1.74 | -0.01 | -0.35 | 0.26 | Upgrade
|
| Asset Writedown | 0.67 | -0.65 | -159.38 | -0.07 | -5.16 | Upgrade
|
| Other Unusual Items | - | -2.53 | 2.12 | 8.02 | 0.19 | Upgrade
|
| Pretax Income | -189.56 | -170.76 | -453.42 | -276.37 | -120.38 | Upgrade
|
| Income Tax Expense | 6.74 | 17.42 | -28.16 | -29.98 | -10.52 | Upgrade
|
| Earnings From Continuing Operations | -196.29 | -188.18 | -425.27 | -246.4 | -109.86 | Upgrade
|
| Minority Interest in Earnings | -0.54 | -4.25 | -1.93 | -2.53 | -0.96 | Upgrade
|
| Net Income | -196.84 | -192.43 | -427.2 | -248.93 | -110.82 | Upgrade
|
| Net Income to Common | -196.84 | -192.43 | -427.2 | -248.93 | -110.82 | Upgrade
|
| Shares Outstanding (Basic) | 354 | 354 | 354 | 307 | 357 | Upgrade
|
| Shares Outstanding (Diluted) | 354 | 354 | 354 | 307 | 357 | Upgrade
|
| Shares Change (YoY) | -0.00% | 0.00% | 15.04% | -14.03% | 0.12% | Upgrade
|
| EPS (Basic) | -0.56 | -0.54 | -1.21 | -0.81 | -0.31 | Upgrade
|
| EPS (Diluted) | -0.56 | -0.54 | -1.21 | -0.81 | -0.31 | Upgrade
|
| Free Cash Flow | -5.08 | 31.22 | 55.91 | -52.13 | -242.66 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | 0.09 | 0.16 | -0.17 | -0.68 | Upgrade
|
| Gross Margin | 43.15% | 44.01% | 41.96% | 39.92% | 41.80% | Upgrade
|
| Operating Margin | -7.66% | -11.08% | -17.27% | -9.18% | -3.26% | Upgrade
|
| Profit Margin | -21.17% | -17.85% | -37.10% | -18.20% | -7.79% | Upgrade
|
| Free Cash Flow Margin | -0.55% | 2.90% | 4.86% | -3.81% | -17.06% | Upgrade
|
| EBITDA | -7.17 | -43.23 | -98 | -33.42 | 50.94 | Upgrade
|
| EBITDA Margin | -0.77% | -4.01% | -8.51% | -2.44% | 3.58% | Upgrade
|
| D&A For EBITDA | 64.01 | 76.24 | 100.84 | 92.13 | 97.35 | Upgrade
|
| EBIT | -71.18 | -119.47 | -198.84 | -125.56 | -46.41 | Upgrade
|
| EBIT Margin | -7.66% | -11.08% | -17.27% | -9.18% | -3.26% | Upgrade
|
| Revenue as Reported | - | 1,078 | 1,151 | 1,368 | 1,422 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.